Aldeyra Therapeutics Inc (NASDAQ: ALDX) has seen a rise in its stock price by 1.15% in relation to its previous close of $4.33. However, the company has experienced a 11.45% gain in its stock price over the last five trading sessions. seekingalpha.com reported 2025-07-02 that Aldeyra Therapeutics’ Reproxalap is now on its third NDA, which was filed in June 2025. It supposedly fixes prior trial flaws. ALDX believes a potential FDA acceptance could set a PDUFA date for December 2025. After that, AbbVie may pay $100 million upfront and share US profits if Reproxalap wins approval, which should materially de-risk its eventual commercialization.
Is It Worth Investing in Aldeyra Therapeutics Inc (NASDAQ: ALDX) Right Now?
Additionally, the 36-month beta value for ALDX is 0.73. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for ALDX is 58.15M and currently, short sellers hold a 7.73% ratio of that float. The average trading volume of ALDX on July 09, 2025 was 1.19M shares.
ALDX’s Market Performance
The stock of Aldeyra Therapeutics Inc (ALDX) has seen a 11.45% increase in the past week, with a 64.66% rise in the past month, and a 124.62% gain in the past quarter. The volatility ratio for the week is 7.51%, and the volatility levels for the past 30 days are at 8.72% for ALDX. The simple moving average for the last 20 days is 24.41% for ALDX stock, with a simple moving average of -4.10% for the last 200 days.
Analysts’ Opinion of ALDX
Many brokerage firms have already submitted their reports for ALDX stocks, with Oppenheimer repeating the rating for ALDX by listing it as a “Outperform.” The predicted price for ALDX in the upcoming period, according to Oppenheimer is $10 based on the research report published on April 03, 2024 of the previous year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see ALDX reach a price target of $10. The rating they have provided for ALDX stocks is “Buy” according to the report published on April 02nd, 2024.
H.C. Wainwright gave a rating of “Buy” to ALDX, setting the target price at $15 in the report published on April 27th of the previous year.
ALDX Trading at 55.29% from the 50-Day Moving Average
After a stumble in the market that brought ALDX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -39.17% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ALDX starting from PERCEPTIVE ADVISORS LLC, who sale 3,400,000 shares at the price of $1.42 back on Apr 03 ’25. After this action, PERCEPTIVE ADVISORS LLC now owns 5,875,851 shares of Aldeyra Therapeutics Inc, valued at $4,828,000 using the latest closing price.
Machatha Stephen, the Chief Development Officer of Aldeyra Therapeutics Inc, sale 16,041 shares at $4.74 during a trade that took place back on Aug 12 ’24, which means that Machatha Stephen is holding 236,771 shares at $75,975 based on the most recent closing price.
Stock Fundamentals for ALDX
Current profitability levels for the company are sitting at:
- -250.08 for the present operating margin
- 0.5 for the gross margin
The net margin for Aldeyra Therapeutics Inc stands at -235.96. The total capital return value is set at -0.77. Equity return is now at value -65.19, with -49.21 for asset returns.
Based on Aldeyra Therapeutics Inc (ALDX), the company’s capital structure generated 0.2 points at debt to capital in total, while cash flow to debt ratio is standing at -2.94. The debt to equity ratio resting at 0.24. The interest coverage ratio of the stock is -32.0.
Currently, EBITDA for the company is -60.12 million with net debt to EBITDA at 0.63. When we switch over and look at the enterprise to sales, we see a ratio of 930.61. The receivables turnover for the company is 0.32for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.39.
Conclusion
In conclusion, Aldeyra Therapeutics Inc (ALDX) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
